Perceptive Capital Solutions Corp

PCSC

Held by 3 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

3 funds opened new positions. Short interest: 8.6% of float.

Share

Shell CompaniesCEO: Adam Leo StoneIPO: 2024Website ↗

Perceptive Capital Solutions Corp does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities operating in the life sciences and medical technology sectors in North America or Europe. Perceptive Capital Solutions Corp was incorporated in 2024 and is based in New York, New York.

Signal Score

4.5/10

3 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 3 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

3 fund convergence

Commodore Capital

RA Capital ManagementHeld 7Q

RTW InvestmentsHeld 7Q

Position history (shares)

Commodore Capital

6Q

RA Capital Management

7Q

RTW Investments

7Q

AI Signal

Signal Note: RA Capital enters PCSC with $7.5M position

RA Capital's $7.5M initiation of PCSC adds to existing conviction from RTW Investments and Commodore Capital, suggesting three specialist funds see asymmetric risk/reward in the SPAC structure. Without visibility into PCSC's target or cash position, the near-term catalyst timeline and dilution risk cannot be assessed; however, the triple-fund convergence indicates meaningful differentiated conviction among sophisticated biotech investors.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

May 15, 2025

$23.1M

3 funds

Aug 14, 2025

$23.8M

3 funds

Nov 14, 2025

$23.7M

3 funds

Feb 17, 2026

$19.4M

2 funds

-14% total institutional value over 7 quarters

Short Interest

High short interest

Short Shares

745K

Change

+0.3%

Days to Cover

14.6

% of Float

8.6%

Settlement

Apr 30, 2026

Short interest over 5 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ACommodore Capital0.0%Feb 17, 2026

SC 13DRA Capital Management8.4%Dec 12, 2025

SC 13GRTW Investments8.3%Nov 14, 2024

SC 13GRA Capital Management8.4%Jun 24, 2024

SC 13GCommodore Capital7.0%Jun 21, 2024

Position Details

Commodore CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

20 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

BLTE1 fund CLYM1 fund EWTX1 fund TSHA1 fund WAY1 fund WGSWW1 fund WVE1 fund OVID1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer